<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58595">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01766934</url>
  </required_header>
  <id_info>
    <org_study_id>EP06-501</org_study_id>
    <nct_id>NCT01766934</nct_id>
  </id_info>
  <brief_title>Non-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell Donors</brief_title>
  <official_title>Non-interventional, Prospective, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Healthy Unrelated Stem Cell Donors Undergoing Peripheral Blood Progenitor Cell Mobilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data collection on the safety and efficacy of Zarzio® / Filgrastim HEXAL® in adult healthy
      unrelated stem cell donors undergoing peripheral blood progenitor cell mobilization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Incidence of drug-related adverse events following mobilization with Sandoz' filgrastim.</measure>
    <time_frame>each patient will be followed for 10 years after mobilization</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary objective is to investigate adverse events that are suspected to be related to stem cell mobilization with the Sandoz' filgrastim in healthy unrelated donors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessment in terms of the CD34+ cell count.</measure>
    <time_frame>CD34+ cells are counted on 1 day immediately preceding apheresis</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary objective is to investigate the efficacy of stem cell mobilization with the Sandoz' filgrastim in terms of the CD34+ cell count.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Peripheral Blood Progenitor Cell Mobilization With G-CSF</condition>
  <eligibility>
    <study_pop>
      <textblock>
        adult, unrelated, healthy volunteers who received at least one dose of Sandoz' filgrastim
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  none

        Exclusion Criteria:

          -  Related to recipient

          -  Chronic significant organ diseases

          -  Systemic autoimmune diseases

          -  Chronic infectious diseases

          -  History of malignant disease

          -  Pregnant and breastfeeding women

          -  Hypersensitivity to E. coli derived proteins

          -  Hypersensitivity to the active substance or to any of the excipients of the
             Sandoz' filgrastim

          -  Absolute and relative contraindications as specified in the summary of product
             characteristics of  the Sandoz` filgrastim

          -  Participation in previous stem cell mobilization procedures

          -  Previous or concurrent use of other mobilising agents, e.g. plerixafor

          -  Donor is unwilling to give written informed consent to his/her study participation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Halvard Bönig, Dr. med, M.A., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood Donor Service Baden-Wuerttemberg Hessen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Halvard Bönig, Dr. med. M.A., MD</last_name>
    <role>Study Chair</role>
    <affiliation>Blood Donor Service Baden-Wuerttemberg Hessen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandoz</last_name>
    <phone>+49 8024 476</phone>
    <phone_ext>0</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen</name>
      <address>
        <city>Frankfurt/Main</city>
        <state>Hessen</state>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halvard Bönig, Dr.med. M.A., MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 16, 2013</lastchanged_date>
  <firstreceived_date>January 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral blood progenitor cell (PBPC) mobilization</keyword>
  <keyword>allogenic hematopoetic stem cell transplantation (HSCT)</keyword>
  <keyword>recombinant human granulocyte colony stimulating factor (rhG-CSF)</keyword>
  <keyword>filgrastim</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
